ESC 365 - Repeat coronary revascularization in high-risk patients treated with ticagrelor monotherapy after PCI: Insights from the randomized TWILIGHT trial

ESC Professional Premium Access

Repeat coronary revascularization in high-risk patients treated with ticagrelor monotherapy after PCI: Insights from the randomized TWILIGHT trial

Session: Antithrombotic therapy in acute coronary syndromes and PCI

Topic: Antiplatelet Drugs

Speaker: Professor R. Mehran (New York, US)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor Roxana Mehran

Icahn School of Medicine at Mount Sinai, New York (United States of America)

53 presentations

12 followers

6 more presentations in this session

Pharmacodynamic and pharmacokinetic profiles associated with switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the SWAP-6 study

Speaker: Doctor M. Galli (Rome, IT)

Pattern of dual antiplatelet use and 12-month outcomes stratified by bleeding and ischemic risk in acute coronary syndrome patients undergoing percutaneous coronary intervention

Speaker: Doctor A. Lai (Shatin, HK)

Mortality with bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome

Speaker: Doctor M. Galli (Rome, IT)

In vitro comparison of platelet aggregation between zalunfiban and selatogrel in healthy donors

Speaker: Mr S. Rikken (Nieuwegein, NL)

Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction

Speaker: Doctor S. Godtfredsen (Aalborg, DK)

Access the full session

Antithrombotic therapy in acute coronary syndromes and PCI

Speakers: Professor R. Mehran, Doctor M. Galli, Doctor A. Lai, Doctor M. Galli, Mr S. Rikken...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources